国药现代：全资子公司国药容生获得布美他尼注射液药品注册证书

Core Viewpoint - The announcement highlights that China National Pharmaceutical Group Modern (国药现代) has received approval for the registration of Bumetanide Injection from the National Medical Products Administration, indicating a significant development in the company's pharmaceutical offerings [1] Group 1 - The full subsidiary of the company, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., is responsible for the newly approved Bumetanide Injection [1] - Bumetanide Injection is primarily indicated for conditions such as edema diseases, hypertension, prevention of acute renal failure, hyperkalemia, and hypercalcemia [1]